CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 13 enrolled
Drug / intervention
Fluzone® +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03023553
NCT03023553Phase 4Completed
CompareCT.gov

The Human Mucosal Immune Responses to Influenza Virus: A Systems Biology Approach. Innate Immune Responses to Influenza Virus in Single Human Nasal Epithelial Cells

Stanford University·interventional·Posted Jan 18, 2017·Updated Apr 21, 2017

In Brief

A Phase 4 clinical trial evaluating Fluzone® and FluMist® for Influenza. Completed, enrolled 13 participants.

Detailed Summary

This study will examine the immune responses to the seasonal influenza vaccine in single cells of the nasal passages when compared with cells in circulating blood.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
Countries--
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 18, 2017
Enrollment StartDec 1, 2012
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.5 years ago

Interventions

Fluzone®biological

Influenza Virus Vaccine Suspension for Intramuscular Injection

FluMist®biological

Influenza Virus Vaccine Live, Intranasal Spray